Follicular Lymphoma Overview
Follicular lymphoma, an indolent B-cell non-Hodgkin’s lymphoma arising from germinal center B cells, continues to represent one of the most prevalent indolent NHL subtypes, accounting for nearly a quarter of all NHL diagnoses. According to DelveInsight’s latest market assessment, the Follicular Lymphoma market size across the 7MM is projected to expand from USD 1,702 million in 2025 to USD 3,081 million by 2036, reflecting a CAGR of 6.8%. In 2024, roughly 35,000 diagnosed cases were recorded across the 7MM, with females representing the larger share at approximately 18,000 cases. The United States led with around USD 1,000 million in revenue, driven by an established treatment base and rapid adoption of novel immunotherapies.
Explore comprehensive Follicular Lymphoma market trends and forecast insights
Follicular Lymphoma Disease Recent Developments
- In July 2026, AbbVie secured European Commission marketing authorization for TEPKINLY (epcoritamab) combined with lenalidomide and rituximab, the first chemotherapy-free bispecific-based regimen approved in Europe for second-line relapsed/refractory follicular lymphoma, cutting progression or death risk by 79% versus standard therapy.
- In February 2025, Regeneron resubmitted its BLA for odronextamab in relapsed/refractory follicular lymphoma to the FDA.
- In January 2025, CRISPR Therapeutics outlined plans to engage regulators on CTX112 for B-cell malignancies.
Follicular Lymphoma Disease Overview
Follicular lymphoma is a chronic, generally incurable but slow-progressing lymphoproliferative disorder marked by diffuse lymphadenopathy, bone marrow involvement, and, in some cases, splenomegaly. Diagnosis relies on excisional lymph node biopsy, immunohistochemical staining for CD19, CD20, CD10, and bcl-2, and detection of the characteristic t(14;18) translocation. Staging typically involves CT and PET imaging alongside bone marrow assessment. Disease course varies widely, with many patients managed initially through observation before requiring systemic therapy.
Follicular Lymphoma Treatment Landscape
Current management depends heavily on disease stage. Asymptomatic, low-bulk disease is often observed without intervention, as early treatment offers no overall survival benefit. Patients needing therapy typically receive chemoimmunotherapy, with rituximab maintenance improving outcomes further. Approved options now span monoclonal antibodies, bispecific T-cell engagers, BTK inhibitors, and CAR-T therapies, including GAZYVA, TAZVERIK, EPKINLY/TEPKINLY, LUNSUMIO, YESCARTA, BREYANZI, KYMRIAH, BRUKINSA, ORDSPONO, and RITUXAN HYCELA. LUNSUMIO (Roche) and BRUKINSA (BeiGene) have each secured accelerated approvals for relapsed/refractory disease, reflecting the shift toward chemotherapy-free regimens in later treatment lines.
Follicular Lymphoma Pipeline Insight
The Follicular Lymphoma pipeline remains active, with bispecific antibodies, next-generation antibody-drug conjugates, and allogeneic CAR-T constructs advancing through late-stage development. Key candidates include MONJUVI (tafasitamab), AZD0486, Golcadomide, Abexinostat, NKTR-255, CTX112, and IMPT-314, backed by companies such as Roche, Gilead/Kite, Novartis, AstraZeneca, BeiGene, Regeneron, and Incyte Corporation. AstraZeneca’s AZD0486 has shown a 96% overall response rate in early trials, while Incyte’s tafasitamab combination met its primary progression-free survival endpoint in the Phase III inMIND study.
Follicular Lymphoma Epidemiology and Market Dynamics
The Follicular Lymphoma epidemiology segment shows the US carrying the highest disease burden, with the 60–80 age group most affected. Stage IV cases made up roughly 35% of the total in 2024, and the EU4 plus UK region recorded around 14,000 cases, led by Germany. On the commercial side, the US commanded over 65% of 7MM market share in 2024, while Spain trailed with the smallest share among EU4 and UK markets. Adoption of emerging therapies will hinge on demonstrated survival and quality-of-life gains relative to cost, toxicity, and payer constraints, shaping the competitive dynamics of the broader Follicular Lymphoma treatment ecosystem through 2036.
Follicular Lymphoma Drivers
- Increasing prevalence and improved diagnosis of follicular lymphoma are expanding the eligible patient population for treatment.
- Growing adoption of targeted therapies, monoclonal antibodies, and combination regimens is driving market growth.
- A robust pipeline of novel immunotherapies, bispecific antibodies, and CAR-T cell therapies is improving treatment outcomes.
- Rising investments in oncology research, clinical trials, and precision medicine are accelerating the development of innovative follicular lymphoma therapies.
- Favorable regulatory approvals, expanding healthcare access, and increasing awareness among patients and healthcare professionals are supporting the growth of the follicular lymphoma market.
Follicular Lymphoma Barriers
- High treatment costs and limited reimbursement policies restrict patient access to advanced Follicular Lymphoma therapies in several regions.
- Disease relapse and the development of treatment resistance continue to challenge long-term disease management and clinical outcomes.
- Delayed diagnosis due to the slow-growing nature and nonspecific symptoms of Follicular Lymphoma can postpone timely intervention.
- Safety concerns associated with novel targeted therapies and immunotherapies, including adverse events, may limit their widespread adoption.
- Stringent regulatory requirements, lengthy clinical development timelines, and intense market competition create barriers to the introduction of innovative Follicular Lymphoma treatments.
Access in-depth Follicular Lymphoma treatment and pipeline analysis today
Conclusion
With an established multi-modal treatment landscape and a robust late-stage pipeline of bispecific antibodies, ADCs, and cell therapies, the follicular lymphoma space is set for continued transformation through 2036. Rising incidence, an aging population, and improved diagnostics will sustain demand, while newer chemotherapy-free regimens offer the potential for deeper, more durable remissions. As reimbursement frameworks evolve across the US, EU4, UK, and Japan, stakeholders that balance efficacy, safety, and affordability will be best positioned to capture share in this expanding market.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: abhishek@delveinsight.com
